表紙
市場調査レポート

マイクロニードルドラッグデリバリーシステム 2020年

Microneedle Drug Delivery Systems to 2020

発行 Greystone Research Associates 商品コード 250428
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
マイクロニードルドラッグデリバリーシステム 2020年 Microneedle Drug Delivery Systems to 2020
出版日: 2015年12月01日 ページ情報: 英文
担当者のコメント
Greystone Research AssociatesはDDSを専門とする調査会社でDDSの細かなテーマを選びそれぞれ独立したレポートとしてまとめています。本レポートではマイクロニードルDDS市場を様々な側面から分析しています。製品の設計にインパクトを与えると思われる技術や、製品の形状などといったユニークな視点が本レポートの特徴です。
概要

当レポートでは、マイクロニードルドラッグデリバリー市場について取り上げ、マイクロニードルデバイス・システムに提供されている認可薬、デバイスの仕様、および販売者、マイクロニードルドラッグデリバリーデバイス・システムのサプライヤーとその製造インフラ、ロケーションおよび能力、マイクロニードルドラッグデリバリーの需要影響因子、マイクロニードルの設計 & 技術、およびマイクロニードルデリバリー製品の重要な治療市場とその市場シェアなどについて調査分析しています。

エグゼクティブサマリー

マイクロニードルの設計 & 技術

  • マイクロニードル製品の分類
  • シリンジ付きマイクロニードル
  • マイクロニードルアレイ & アレイ形状
  • マイクロニードル製造

マイクロニードルドラッグデリバリー:市場要因

  • ドラッグデリバリー & 自己投与
  • アンメットニーズ
  • 慢性疾患 & 投薬頻度
  • 患者安全性・コンプライアンス
  • 市場成長促進因子

マイクロニードルドラッグデリバリーの評価

  • ブランドプラットフォーム
  • ブランドデバイス
  • 併用製品
  • 開発段階にあるデバイス

短期的市場:部門評価および予測

  • 遺伝子/DNA/ヌクレオチド治療
  • インスリン
  • 代謝条件
  • 神経学
  • 骨粗しょう症
  • ワクチン

企業プロファイル

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MND899T

Engineering the Next Transdermal Technology

Microneedle technology is attaining commercial viability at a time when drug developers are faced with new challenges as they assess ways to administer new classes of compounds with significant therapeutic potential. The widespread availability of rapid throughput screening is accelerating the discovery of new drugs, a significant number of which are large-molecule therapeutic compounds that cannot tolerate passage through the digestive system, requiring pharmaceutical companies to forego oral formulations and select alternate routes of administration. Microneedle technology has the potential address the growing trend toward self-administration by allowing the precise placement of therapeutic agents at prescribed locations below the skin. To succeed, developers must refine the techniques for large-scale manufacturing and advance the design integration of microneedles into commercially viable drug delivery systems.

What Your Will Learn

  • What approved drug products are currently supplied in microneedle devices and systems, what are the device specifics, and who markets them?
  • Who are the branded microneedle drug delivery device and system suppliers, their manufacturing infrastructure and locations, their capabilities?
  • What are the major factors that are influencing demand for microneedle drug delivery?
  • How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
  • What are the essential design factors, material selection issues, technologies and market development issues for microneedle drug delivery products?
  • What are the important therapeutic markets for microneedle delivery products and what is their market share now? What will it be in 2020?
  • What are the significant economic, technology, and regulatory factors affecting the market for prefilled syringes?

Market-driven Product Strategies

A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.

‘Evolution in drug delivery device design is changing the way a growing number of therapeutic substances are administered. This trend is being fostered by the desire by patients for more user friendly methods for self-medicating, and by the need for safer, more reliable drug products that improve compliance. For drugs capable of being administered across the skin, intradermal delivery is viewed as an approach that addresses these key healthcare objectives. Intradermal delivery offers several advantages when compared to alternative technologies, including being minimally invasive and inducing minimal trauma during delivery.'

Table of Contents

Executive Summary

Microneedle Design & Technology

  • Microneedle Product Categories
    • Solid Microneedles
    • Hollow Microneedles
    • Coated Microneedles
    • Dissolving Microneedles
  • Syringe-mounted Microneedles
  • Microneedle Arrays & Array Geometries
  • Microneedle Manufacturing
    • Material Selection Issues
    • Fabrication Techniques
    • Emerging Fabrication Methods

Microneedle Drug Delivery - Market Factors

  • Drug Delivery & Self-Administration
  • Unmet Needs
  • Chronic Conditions & Dosing Frequency
  • Patient Safety and Compliance
  • Market Drivers
    • Shifting Patient Demographics
    • Vaccine Dose Sparing
    • Managed Care Initiatives
    • Government Technology Transfer Programs

Microneedle Drug Delivery Assessments

  • Branded Platforms
    • DebioJect
    • Libertas
    • MicroCor
    • Micronjet
    • Soluvia
    • MTS
  • Branded Devices
    • Memspatch
    • Micro-Patch
  • Combination Products
    • Insulin
      • V-GO
    • PTH
      • McirCor PTH
      • ZP-PTH
      • Abaloparatide-SC
  • Development-stage Devices
    • Micro-Trans
    • Nanopatch
    • PKA SoftTouch

Near-Terms Markets - Sector Assessments and Forecasts

  • Genetic/DNA/Nucleotide Therapeutics
  • Insulin
  • Metabolic Conditions
  • Neurology
  • Osteoporosis
  • Vaccines

Company Profiles

Back to Top